JOP20170131B1 - مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان - Google Patents
مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطانInfo
- Publication number
- JOP20170131B1 JOP20170131B1 JOP/2017/0131A JOP20170131A JOP20170131B1 JO P20170131 B1 JOP20170131 B1 JO P20170131B1 JO P20170131 A JOP20170131 A JO P20170131A JO P20170131 B1 JOP20170131 B1 JO P20170131B1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer
- compounds
- dihydro
- trahydropyranylcarbonyl
- indole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات 2، 3-داي هيدرو-1H- إندول جديدة معينة، تركيبات صيدلية تشتمل على المركبات، وطرق استخدام المركبات لعلاج السرطان، وبصورة أكثر تحديدًا لعلاج السرطان تم اختيارها من المجموعة المتكونة من الورم الميلانيني، اللوكيميا النخاعية الحادة، لوكيميا الخلايا اللمفية المزمنة، سرطان القولون والمستقيم، سرطان الثدي، سرطان الرئة، سرطان المبيض، كارسينوما قناة فالوب، الكارسينوما البريتونية الرئيسية، السرطان العنقي، السرطان المعدي، سرطان الكبد، سرطان البنكرياس، سرطان الغدة الدرقية، الورم النخاعي، الورم اللمفاوي غير هودكينز، والورم اللمفاوي هودكينز.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20170131B1 true JOP20170131B1 (ar) | 2021-08-17 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2017/0131A JOP20170131B1 (ar) | 2016-06-10 | 2017-05-24 | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US10759786B2 (ar) |
| EP (1) | EP3468965B1 (ar) |
| JP (1) | JP6632746B2 (ar) |
| KR (1) | KR102241258B1 (ar) |
| CN (1) | CN109641881B (ar) |
| AR (1) | AR108586A1 (ar) |
| AU (1) | AU2017277833B2 (ar) |
| BR (1) | BR112018072872A2 (ar) |
| CA (1) | CA3027035C (ar) |
| CL (1) | CL2018003543A1 (ar) |
| CO (1) | CO2018013251A2 (ar) |
| CR (1) | CR20180579A (ar) |
| CY (1) | CY1123660T1 (ar) |
| DK (1) | DK3468965T3 (ar) |
| DO (1) | DOP2018000278A (ar) |
| EA (1) | EA037419B1 (ar) |
| EC (1) | ECSP19001734A (ar) |
| ES (1) | ES2797981T3 (ar) |
| HR (1) | HRP20200769T1 (ar) |
| HU (1) | HUE050155T2 (ar) |
| IL (1) | IL263497B (ar) |
| JO (1) | JOP20170131B1 (ar) |
| LT (1) | LT3468965T (ar) |
| MA (1) | MA45224B1 (ar) |
| MD (1) | MD3468965T2 (ar) |
| ME (1) | ME03744B (ar) |
| MX (1) | MX2018015275A (ar) |
| MY (1) | MY197462A (ar) |
| NZ (1) | NZ748500A (ar) |
| PE (1) | PE20190378A1 (ar) |
| PH (1) | PH12018502572A1 (ar) |
| PL (1) | PL3468965T3 (ar) |
| PT (1) | PT3468965T (ar) |
| RS (1) | RS60322B1 (ar) |
| SG (1) | SG11201809625RA (ar) |
| SI (1) | SI3468965T1 (ar) |
| TW (1) | TWI671294B (ar) |
| UA (1) | UA122526C2 (ar) |
| WO (1) | WO2017213919A1 (ar) |
| ZA (1) | ZA201807688B (ar) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| KR102556744B1 (ko) | 2017-08-28 | 2023-07-18 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| EP3727374A4 (en) * | 2017-12-21 | 2021-11-10 | Merck Patent GmbH | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11992489B2 (en) | 2018-08-17 | 2024-05-28 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| AR116474A1 (es) | 2018-09-21 | 2021-05-12 | Enanta Pharm Inc | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV |
| EP3877366A4 (en) * | 2018-11-06 | 2022-08-24 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
| AU2019385477A1 (en) | 2018-11-21 | 2021-06-10 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4629657B2 (ja) * | 2003-04-11 | 2011-02-09 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物 |
| HUE029214T2 (en) * | 2005-05-10 | 2017-02-28 | Incyte Holdings Corp | Indolamine-2,3-dioxygenase modulators and methods for their use |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| CN101990537A (zh) * | 2008-02-07 | 2011-03-23 | 雅培制药有限公司 | 作为阳性别构调节剂的酰胺衍生物和其使用方法 |
| NZ590268A (en) * | 2008-07-08 | 2012-11-30 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| NO2694640T3 (ar) * | 2011-04-15 | 2018-03-17 | ||
| SG11201506920QA (en) * | 2013-03-15 | 2015-09-29 | Bristol Myers Squibb Co | Ido inhibitors |
| JP6554117B2 (ja) * | 2014-04-04 | 2019-07-31 | イオメット ファーマ リミテッド | 医療で使用されるインドール誘導体 |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| WO2017112955A1 (en) * | 2015-12-23 | 2017-06-29 | Pharma Llc Moonshot | Methods for inducing an immune response by inhibition of nonsense mediated decay |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es unknown
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh active
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh active Active
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro unknown
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/es unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja active Active
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko active IP Right Grant
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20170131B1 (ar) | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
| PH12020500033A1 (en) | Macrocyclic compounds and uses thereof | |
| MX2021003389A (es) | Metodos para tratar el cancer. | |
| WO2017176628A8 (en) | Methods for solid tumor treatment | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| JOP20200152A1 (ar) | مركبات حلقية كبرى لعلاج مرض | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
| MX2022001019A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). | |
| PH12019500957A1 (en) | Selective inhibitor of exon 20 insertion mutant egfr | |
| PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| MX2020011344A (es) | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| WO2019023315A3 (en) | RAC INHIBITORS | |
| MX2019014845A (es) | Compuestos de aminotiazol como inhibidores de la proteina quinasa. | |
| MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
| MX2018001315A (es) | Inhibidores de fucosidasa. | |
| AU2017242908A1 (en) | Ferric maltol compositions for use in the treatment or prevention of cancer and tumours | |
| MX2021009195A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| PH12020551193A1 (en) | Certain chemical entities, compositions, and methods | |
| MX2018002612A (es) | Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo. | |
| EA201691846A1 (ru) | Композиции и способы лечения рака печени |